RE: Westaim numbersthe difference between Income of $6m and Profit of $20m is the Pharma Development
Costs (the R&D and testing of the new products). these costs aren't considered part of
normal operating profit but they are expensed on the income statement.
the nucryst profit in 2005 may be less than 2004, due to reduced milestone payments, but
clearly nucryst is still worth at least $300m and potentially much more if the Phase 2 plays
out.
combined with the $100m cash, this exceeds the current market cap of WED ... and leaves
a free iFire call for investors who understand
good luck to all